Seagen Inc.
Seagen Inc. (SGEN): 18 pipeline candidates · ~133 mo cash runway · 26 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
133.3 months
0% dilution
Lead: Approved
18 candidates
N/A
N/A
A transparent, data-derived signal for Seagen Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$429.2M
Quarterly Burn
$35.8M
Runway
133.3 mo
Revenue
$648.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (18 candidates)
| Drug | Phase |
|---|---|
| acetylcysteine | Approved |
| ampicillin | Approved |
| ampicillin | Approved |
| calcium gluconate in | Approved |
| calcium gluconate in | Approved |
| cefepime | Approved |
| famotidine | Approved |
| glycopyrrolate | Approved |
| glycopyrrolate | Approved |
| glydo | Approved |
Showing 10 of 18 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Seagen Inc.'s pipeline?
Seagen Inc. (SGEN) has 18 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Seagen Inc.'s lead drug candidate?
Seagen Inc.'s most advanced tracked candidate is acetylcysteine (Approved).
What is Seagen Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Seagen Inc. has approximately 133.3 months of cash runway.
Who is the CEO of Seagen Inc.?
Chief Executive Officer is the chief executive officer of Seagen Inc. (SGEN).
Get the full picture on Seagen Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.